RT Journal Article
SR Electronic
T1 Salbutamol or aminophylline for acute severe asthma: how to choose which one, when and why?
JF Archives of disease in childhood - Education & practice edition
JO Arch Dis Child Educ Pract Ed
FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
SP 215
OP 222
DO 10.1136/archdischild-2014-306186
VO 100
IS 4
A1 Matthew Neame
A1 Octavio Aragon
A1 Ricardo M Fernandes
A1 Ian Sinha
YR 2015
UL http://ep.bmj.com/content/100/4/215.abstract
AB Acute, severe exacerbations of asthma present a challenge due to the significant morbidity associated with this presentation. For exacerbations that are refractory to initial treatments with inhaled and oral therapies, there is still doubt about which intravenous therapies are most likely to be helpful. β-2 agonists and aminophylline have differing mechanisms of action that also affect their adverse effects profiles and these are considered. A review of the available randomised control trials suggests that a bolus of intravenous salbutamol may reduce symptoms and hasten recovery. Aminophylline infusions may improve lung function, and in some studies have been shown to improve symptoms, but the evidence is not clear cut. Decisions about which treatment to use should include risk management considerations such as ease of prescription, preparation and administration factors and availability of high-dependency beds.